-
TIF News (IT)
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird bio that the latter has placed Phase 1/2 and Phase…
Leggi di più » -
Publications
-
NOVITÀ
-
NOVITÀ
NOW PUBLISHED: The TIF ‘’Gene Therapy & Thalassaemia’’ Survey Report
Gene therapy for thalassaemia is an expensive and complex procedure, with great efforts ongoing currently by all involved stakeholders, such as patients, healthcare professionals, etc. to ensure its accessibility and…
Leggi di più » -
Ongoing projects
-
NOVITÀ
The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage clinical trial published yesterday in The Lancet international medical journal.…
Leggi di più » -
Conferences
-
NOVITÀ
EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease
The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application (MAA) for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia in sickle cell disease (SCD). According to the company,…
Leggi di più » -
NOVITÀ
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
Leggi di più » -
NOVITÀ
WHO Maintains Official Relations With TIF For 2021-2024
We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for 2021-2024 The extension of ΤIF’s official relations with WHO was…
Leggi di più »
